FSD Pharma's COVID-19 Drug Candidate Gets Ethics Approval
Ticker: QNTM · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-approval, clinical-trial, drug-development
TL;DR
FSD Pharma's COVID drug candidate FSD-201 cleared ethics review for preclinical study at Uni of São Paulo.
AI Summary
FSD Pharma Inc. filed a Form 6-K on June 27, 2024, to report its activities for June 2024. The filing includes a press release announcing that FSD Pharma has received approval from the Ethics Committee of the Faculty of Medicine at the University of São Paulo for its preclinical study on FSD-201. This study aims to investigate the anti-inflammatory and anti-fibrotic properties of FSD-201 in treating COVID-19.
Why It Matters
This ethics committee approval is a crucial step for FSD Pharma, allowing them to proceed with preclinical testing of FSD-201, potentially validating its therapeutic use for COVID-19.
Risk Assessment
Risk Level: medium — The company is in the early stages of drug development, and the success of preclinical studies does not guarantee regulatory approval or commercial viability.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- FSD-201 (drug_candidate) — Subject of preclinical study
- Ethics Committee of the Faculty of Medicine at the University of São Paulo (organization) — Granted approval for study
- Nathan Coyle (person) — Chief Financial Officer
- June 27, 2024 (date) — Filing date
FAQ
What is the purpose of the preclinical study for FSD-201?
The preclinical study aims to investigate the anti-inflammatory and anti-fibrotic properties of FSD-201 in treating COVID-19.
Which institution approved the preclinical study for FSD-201?
The Ethics Committee of the Faculty of Medicine at the University of São Paulo approved the preclinical study.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on June 27, 2024.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
Nathan Coyle, Chief Financial Officer, signed the Form 6-K.
What is FSD Pharma Inc.'s primary business sector?
FSD Pharma Inc. is in the Pharmaceutical Preparations sector (SIC code 2834).
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-06-27 07:34:23
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 19KB
- fsd_ex991img2.jpg (GRAPHIC) — 6KB
- 0001654954-24-008244.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: June 27, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3